Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207821896> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W3207821896 endingPage "F111" @default.
- W3207821896 startingPage "F107" @default.
- W3207821896 abstract "En présence d’un adénocarcinome localisé, le traitement partiel de la prostate est un traitement émergeant, favorisé par le développement de l’IRM. La sélection des patients est essentielle : Grade Groupes 1 et 2, non éligibles à la surveillance active ou refusant un traitement radical (moins de 3 sextants envahis par lobe) et dont la lésion index est à plus de 9 mm de la zone sphinctérienne. Réalisable par HIFU en ambulatoire, sa tolérance est bien établie : la complication principale est la rétention urinaire (10 %) et les conséquences fonctionnelles sont limitées (continence 91–100 % et maintien de la fonction érectile 64–89 %). L’efficacité est prouvée par l’absence de cancer cliniquement significatif dans la zone traitée dans 87 % (79–96) des cas. À 5 ans de suivi, moins de 20 % des patients auront besoin d’un traitement radical. En attente de validation par un suivi à plus long-terme, les patients doivent être traités dans des études ou des cohortes prospectives établies en accord avec les autorités de santé. In the presence of a localised adenocarcinoma, partial treatment of the prostate is an emerging treatment, greatly enhanced by the development of MRI. Patient selection is essential: grade groups 1 and 2, not eligible for active surveillance or refusing radical treatment (less than 3 sextants invaded per lobe) and whose index lesion is at least 9 mm far away from the sphincter area. Partial gland ablation can be achieved by HIFU on an outpatient basis, with a well-established tolerance: main complication is urinary retention (10%) and functional consequences are limited (continence 91–100% and preservation of erectile function 64–89%). Efficacy is demonstrated by the absence of clinically significant cancer in the treated area in 87% (79–96) of cases. At 5 years of follow-up, less than 20% of patients will need radical treatment. Pending validation by longer-term follow-up, patients should be treated through clinical studies or prospective cohorts in agreement with health authorities." @default.
- W3207821896 created "2021-10-25" @default.
- W3207821896 creator A5005618200 @default.
- W3207821896 creator A5049580074 @default.
- W3207821896 date "2021-12-01" @default.
- W3207821896 modified "2023-09-30" @default.
- W3207821896 title "Traitement « focal » de l’adénocarcinome prostatique par HIFU" @default.
- W3207821896 cites W1663630120 @default.
- W3207821896 cites W1976270613 @default.
- W3207821896 cites W1998192955 @default.
- W3207821896 cites W2064617523 @default.
- W3207821896 cites W2098693987 @default.
- W3207821896 cites W2110569728 @default.
- W3207821896 cites W2139000771 @default.
- W3207821896 cites W2143962930 @default.
- W3207821896 cites W2439583849 @default.
- W3207821896 cites W2513452278 @default.
- W3207821896 cites W2523396458 @default.
- W3207821896 cites W2528302844 @default.
- W3207821896 cites W2566433825 @default.
- W3207821896 cites W2803571750 @default.
- W3207821896 cites W2810125259 @default.
- W3207821896 cites W2895620602 @default.
- W3207821896 cites W2905153461 @default.
- W3207821896 cites W2916798133 @default.
- W3207821896 cites W2965847361 @default.
- W3207821896 doi "https://doi.org/10.1016/j.fpurol.2021.09.001" @default.
- W3207821896 hasPublicationYear "2021" @default.
- W3207821896 type Work @default.
- W3207821896 sameAs 3207821896 @default.
- W3207821896 citedByCount "0" @default.
- W3207821896 crossrefType "journal-article" @default.
- W3207821896 hasAuthorship W3207821896A5005618200 @default.
- W3207821896 hasAuthorship W3207821896A5049580074 @default.
- W3207821896 hasBestOaLocation W32078218961 @default.
- W3207821896 hasConcept C121608353 @default.
- W3207821896 hasConcept C126322002 @default.
- W3207821896 hasConcept C2780192828 @default.
- W3207821896 hasConcept C2994223898 @default.
- W3207821896 hasConcept C71924100 @default.
- W3207821896 hasConceptScore W3207821896C121608353 @default.
- W3207821896 hasConceptScore W3207821896C126322002 @default.
- W3207821896 hasConceptScore W3207821896C2780192828 @default.
- W3207821896 hasConceptScore W3207821896C2994223898 @default.
- W3207821896 hasConceptScore W3207821896C71924100 @default.
- W3207821896 hasIssue "4" @default.
- W3207821896 hasLocation W32078218961 @default.
- W3207821896 hasOpenAccess W3207821896 @default.
- W3207821896 hasPrimaryLocation W32078218961 @default.
- W3207821896 hasRelatedWork W1995515455 @default.
- W3207821896 hasRelatedWork W2080531066 @default.
- W3207821896 hasRelatedWork W2141286233 @default.
- W3207821896 hasRelatedWork W2748952813 @default.
- W3207821896 hasRelatedWork W2899084033 @default.
- W3207821896 hasRelatedWork W2944897644 @default.
- W3207821896 hasRelatedWork W3023770452 @default.
- W3207821896 hasRelatedWork W3031052312 @default.
- W3207821896 hasRelatedWork W3032375762 @default.
- W3207821896 hasRelatedWork W55456480 @default.
- W3207821896 hasVolume "31" @default.
- W3207821896 isParatext "false" @default.
- W3207821896 isRetracted "false" @default.
- W3207821896 magId "3207821896" @default.
- W3207821896 workType "article" @default.